Drug Trial Radar · NCT00115648
Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission
Last checked: Nov 20, 2026Latest source record: Mar 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,300
Planned (sponsor's estimate)
Start
Apr 2004
Primary completion
Aug 2007
Study completion Oct 2009
Sponsor
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Jun 24, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 54 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if extended antiretroviral regimens given to the infant during the first 14 weeks of age would decrease breast milk transmission of HIV.
Conditions
- HIV Infections
Interventions
NevirapineDrug
Oral NVP daily dosage
AZTDrug
Oral AZT daily
NVP and AZTDrug
Oral single dose NVP plus oral daily AZT during the first weeks
NVPDrug
Oral NVP daily to age 14 weeks
NVP+AZTDrug
Oral NVP daily plus oral AZT daly to age 14 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- A. Rate of HIV infection at 9 months and assess HIV infection rates at 6-8 & 14 weeks, and 6, 12, 18, and 24 months. B.Determine HIV survival rates at ages 6, 12, 18, and 24 months. C. Evaluate safety of oral NVP and ZDV for 14 weeks.Time frame: 9 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
College of Medicine
Blantyre, Malawi
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.